Articles

MDoutlook® Delivers Precision Intelligence

The latest release from our annual corporate leadership reveals multiple factors supporting the use of an IO approach having similar impact on treatment decisions. Factors most driving oncologist usage were efficacy and quality of life benefits offered by IO treatments followed by label safety and availability of biomarkers. With little
Read more
With ASCO announcing their inaugural virtual program last week and ahead of other major oncology and hematology conferences (such as EHA) moving online, client appetite for planning their activities have not abated in hiring us to measure impact of their data announcement activity in the current “new norm”. Have you
Read more
Having recently named the 2020 leaders in oncology and ImmunoOncology, our latest release from our annual Corporate Leadership report reveals the key attributes oncologists view as driving successful leadership in IO. “Products” and “R&D/Product Pipeline” are the two most important aspects driving oncologists’ view of Corporate Leadership. The top five
Read more
In our latest annual series exploring corporate leadership (in oncology and IO), oncologists shared their views to reveal BMS (and Celgene), Merck & Co and Roche / Genentech as dominant in oncology and ImmunoOncology. Today’s corporate leaders dominated in 2019 with oncologist preferences showing consistency in their ranking companies (year
Read more
Most life science companies strategize to engage ThoughtLeaders with the majority of clients deploying engagement strategies during Phase 3 / launch. A small number target influential ThoughtLeaders earlier (pre-clinical/pre-launch) building long-term valuable relationships (‘brand ambassadors”) within scientific and physician communities. Along the product journey, MDoutlook empowers clients by engaging experts
Read more
Over the past year, we have helped more clients than ever with timely critical input to their business.  Through our validated and active community of cancer treaters and ThoughtLeaders, we engaged 87,000 physicians worldwide. We have helped clients make confident business decisions in the following ways. Precision ThoughtLeader identification and
Read more
Identifying the right experts is often lengthy and challenging for biopharmaceutical companies and their agencies. At MDoutlook, we streamline the process to gaining precision engagement to the expertise of over 14,000 ThoughtLeaders and 120,000+ qualified treaters in oncology, hematology and rare diseases from over 120 countries. Timing is everything in
Read more
Measuring the impact of data announcements is of importance, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the overall influence and reach of your messages. Having helped numerous biopharmaceutical companies track impact from their messaging activities, our experienced team shares
Read more
Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today. ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare
Read more
Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019. The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where
Read more
The latest release from our annual corporate leadership reveals multiple factors supporting the use of an IO approach having similar impact on treatment decisions. Factors most driving oncologist usage were efficacy and quality of life benefits offered by IO treatments followed by label safety and availability of biomarkers. With little
Read more
With ASCO announcing their inaugural virtual program last week and ahead of other major oncology and hematology conferences (such as EHA) moving online, client appetite for planning their activities have not abated in hiring us to measure impact of their data announcement activity in the current “new norm”. Have you
Read more
Having recently named the 2020 leaders in oncology and ImmunoOncology, our latest release from our annual Corporate Leadership report reveals the key attributes oncologists view as driving successful leadership in IO. “Products” and “R&D/Product Pipeline” are the two most important aspects driving oncologists’ view of Corporate Leadership. The top five
Read more
In our latest annual series exploring corporate leadership (in oncology and IO), oncologists shared their views to reveal BMS (and Celgene), Merck & Co and Roche / Genentech as dominant in oncology and ImmunoOncology. Today’s corporate leaders dominated in 2019 with oncologist preferences showing consistency in their ranking companies (year
Read more
Most life science companies strategize to engage ThoughtLeaders with the majority of clients deploying engagement strategies during Phase 3 / launch. A small number target influential ThoughtLeaders earlier (pre-clinical/pre-launch) building long-term valuable relationships (‘brand ambassadors”) within scientific and physician communities. Along the product journey, MDoutlook empowers clients by engaging experts
Read more
Over the past year, we have helped more clients than ever with timely critical input to their business.  Through our validated and active community of cancer treaters and ThoughtLeaders, we engaged 87,000 physicians worldwide. We have helped clients make confident business decisions in the following ways. Precision ThoughtLeader identification and
Read more
Identifying the right experts is often lengthy and challenging for biopharmaceutical companies and their agencies. At MDoutlook, we streamline the process to gaining precision engagement to the expertise of over 14,000 ThoughtLeaders and 120,000+ qualified treaters in oncology, hematology and rare diseases from over 120 countries. Timing is everything in
Read more
Measuring the impact of data announcements is of importance, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the overall influence and reach of your messages. Having helped numerous biopharmaceutical companies track impact from their messaging activities, our experienced team shares
Read more
Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today. ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare
Read more
Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019. The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where
Read more
The latest release from our annual corporate leadership reveals multiple factors supporting the use of an IO approach having similar impact on treatment decisions. Factors most driving oncologist usage were efficacy and quality of life benefits offered by IO treatments followed by label safety and availability of biomarkers. With little
Read more
With ASCO announcing their inaugural virtual program last week and ahead of other major oncology and hematology conferences (such as EHA) moving online, client appetite for planning their activities have not abated in hiring us to measure impact of their data announcement activity in the current “new norm”. Have you
Read more
Having recently named the 2020 leaders in oncology and ImmunoOncology, our latest release from our annual Corporate Leadership report reveals the key attributes oncologists view as driving successful leadership in IO. “Products” and “R&D/Product Pipeline” are the two most important aspects driving oncologists’ view of Corporate Leadership. The top five
Read more
In our latest annual series exploring corporate leadership (in oncology and IO), oncologists shared their views to reveal BMS (and Celgene), Merck & Co and Roche / Genentech as dominant in oncology and ImmunoOncology. Today’s corporate leaders dominated in 2019 with oncologist preferences showing consistency in their ranking companies (year
Read more
Most life science companies strategize to engage ThoughtLeaders with the majority of clients deploying engagement strategies during Phase 3 / launch. A small number target influential ThoughtLeaders earlier (pre-clinical/pre-launch) building long-term valuable relationships (‘brand ambassadors”) within scientific and physician communities. Along the product journey, MDoutlook empowers clients by engaging experts
Read more
Over the past year, we have helped more clients than ever with timely critical input to their business.  Through our validated and active community of cancer treaters and ThoughtLeaders, we engaged 87,000 physicians worldwide. We have helped clients make confident business decisions in the following ways. Precision ThoughtLeader identification and
Read more
Identifying the right experts is often lengthy and challenging for biopharmaceutical companies and their agencies. At MDoutlook, we streamline the process to gaining precision engagement to the expertise of over 14,000 ThoughtLeaders and 120,000+ qualified treaters in oncology, hematology and rare diseases from over 120 countries. Timing is everything in
Read more
Measuring the impact of data announcements is of importance, tracking follow-up activity from a conference is of even greater importance and should not be overlooked when assessing the overall influence and reach of your messages. Having helped numerous biopharmaceutical companies track impact from their messaging activities, our experienced team shares
Read more
Whilst the importance of conferences such as ASCO and ASH are acknowledged this mantle is shared more than ever today. ESMOs importance has grown significantly in recent years both in terms of size and diversity of audience as well as its reach as a global platform (e.g. more US healthcare
Read more
Cabazitaxel was presented as an option for men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after treatment with docetaxel and an androgen signaling-targeted agent according to data presented at ESMO 2019. The results showed a significant survival benefit for Cabazitaxel in third line over enzalutamide or abiraterone where
Read more
Three Ways to Identify and Activate ThoughtLeaders

3 Ways To Identify And Activate ThoughtLeaders Webinar

In this webinar, we will help you (1) go deeper in identifying your ThoughtLeaders in a specific disease area, (2) to target your ThoughtLeaders for the right type of activity and (3) provide you the foundation for building stronger relationships with specific ThoughtLeaders and their influence networks.

Read More »
Webinar Cover

Performance Tracking To Stay Ahead Of The Curve Webinar

You need brand and market insights yesterday! You are not satisfied with the insights provided because each time you receive them, they are out of date. You want to stay one step ahead. In this webinar, we share ways that you can stay ahead by reacting in time through informed confident business decisions.

Read More »